Search for: "APP Pharmaceuticals, LLC" Results 21 - 40 of 132
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 Sep 2015, 7:16 am
Mike Mireles, writing on IP Finance, records the potential impact upon the pharmaceutical industry of the current contest to occupy the White House. [read post]
12 Aug 2011, 10:06 am
The lawsuit arose from an Abbreviated New Drug Application filed with the Food and Drug Administration that had been filed by Teva Parenteral Medicines of Israel, alleging APP Pharmaceuticals LLC of Schaumburg, Illinois, and Barr Laboratories of Montvale, New Jersey. [read post]
7 Nov 2014, 5:52 am
APP Pharmaceuticals, LLC, 2013 WL 5532767, at *7-8 (D. [read post]
2 Dec 2011, 2:00 pm by Bexis
APP Pharmaceuticals, LLC, 783 F. [read post]
23 Apr 2012, 1:46 pm
Here are a few we have blogged about: Eli Lilly and Company Sues Accord Healthcare for Patent Infringement of Lung Cancer Drug ALIMTA Eli Lilly Company Sues APP Pharmaceuticals LLC for Patent Infringement of Chemotherapy Drug Lilly Wins Patent Infringement Suit Regarding Chemotherapy Drug [read post]
20 Oct 2011, 7:55 am by FDABlog HPM
Court of Appeals for the Federal Circuit notifying the Court of the enactment of Section 37 and asserting that it resolves the merits of the ongoing ‘404 patent PTE litigation with APP Pharmaceuticals, LLC (“APP”) (see our previous posts here, here, and here).  [read post]
28 Feb 2013, 7:46 am
  Eli Lilly has sued alleging infringement of the patented ALIMTA before:  ·         Eli Lilly Sues Apotex Inc. for Patent Infringement of ALIMTA   ·         Eli Lilly and Company Sues Accord Healthcare for Patent Infringement of Lung Cancer Drug ALIMTA ·         Lilly Wins Patent Infringement Suit Regarding Chemotherapy Drug … [read post]
26 Sep 2011, 12:30 pm by FDABlog HPM
Court of Appeals for the Federal Circuit (where APP Pharmaceuticals, LLC (“APP”) has been duking it out with MDCO – see here and here) given all of the twists and turns that have occurred with the ANGIOMAX ‘404 patent PTE over the years.     [read post]